ATE281831T1 - Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen - Google Patents

Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen

Info

Publication number
ATE281831T1
ATE281831T1 AT96926586T AT96926586T ATE281831T1 AT E281831 T1 ATE281831 T1 AT E281831T1 AT 96926586 T AT96926586 T AT 96926586T AT 96926586 T AT96926586 T AT 96926586T AT E281831 T1 ATE281831 T1 AT E281831T1
Authority
AT
Austria
Prior art keywords
diseases caused
anomalities
preventing
agent
treating diseases
Prior art date
Application number
AT96926586T
Other languages
English (en)
Inventor
Satomichi Yoshimura
Kengo Akimoto
Masashi Matsui
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Application granted granted Critical
Publication of ATE281831T1 publication Critical patent/ATE281831T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
AT96926586T 1995-08-07 1996-08-07 Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen ATE281831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20105095 1995-08-07
PCT/JP1996/002231 WO1997005863A1 (fr) 1995-08-07 1996-08-07 Agent preventif ou remede pour guerir des maladies provoquees par des anomalies dans les tissus cartilagineux

Publications (1)

Publication Number Publication Date
ATE281831T1 true ATE281831T1 (de) 2004-11-15

Family

ID=16434574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926586T ATE281831T1 (de) 1995-08-07 1996-08-07 Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen

Country Status (11)

Country Link
US (1) US6765020B2 (de)
EP (1) EP0790056B1 (de)
JP (1) JP4111542B2 (de)
KR (2) KR100490189B1 (de)
AT (1) ATE281831T1 (de)
CA (1) CA2201855C (de)
DE (1) DE69633818T2 (de)
DK (1) DK0790056T3 (de)
ES (1) ES2232839T3 (de)
PT (1) PT790056E (de)
WO (1) WO1997005863A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3995290B2 (ja) * 1996-08-23 2007-10-24 サントリー株式会社 オメガ９系高度不飽和脂肪酸及びそれを含有する脂質の製造方法
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
WO2001028518A1 (de) * 1999-10-20 2001-04-26 Vesifact Ag Cyclosporine enthaltende mikroemulsion-prekonzentrate und mikroemulsionen
US6607745B2 (en) * 2001-05-18 2003-08-19 Harry Leneau Ingestion of hyaluronic acid for improved joint function and health
JP4088097B2 (ja) 2002-04-26 2008-05-21 サントリー株式会社 高度不飽和脂肪酸含有脂質の製造方法
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
FI20060154A7 (fi) 2003-08-18 2006-05-11 Btg Int Ltd Neurogeneratiivisten tilojen hoito
JP4721642B2 (ja) * 2004-01-20 2011-07-13 サントリーホールディングス株式会社 肝障害を伴う肝臓疾患の予防又は改善剤
JP4351932B2 (ja) * 2004-02-27 2009-10-28 キヤノン株式会社 自動原稿搬送装置、画像読み取り装置及び画像形成装置
JP4575105B2 (ja) * 2004-10-07 2010-11-04 ポリエン・プロジェクト有限会社 骨芽細胞活性抑制剤
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
IL206739A (en) 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
JP2012041283A (ja) * 2010-08-17 2012-03-01 Porien Project Kk 血管新生抑制剤
AU2011349718B2 (en) * 2010-12-21 2017-02-09 Nestec S.A. Methods and compositions for preventing and treating osteoarthritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260336A (en) 1992-04-30 1993-11-09 New England Deaconess Hospital Corporation Monounsaturated fat as dietary supplement to minimize the effects of catabolic illness
US5516801A (en) * 1992-08-21 1996-05-14 Scotia Holdings Plc Fatty acid treatment for ectopic calcium deposition
JPH0741421A (ja) * 1993-05-28 1995-02-10 Suntory Ltd ロイコトリエンｂ４ （ｌｔｂ４ ）による医学的症状の予防及び改善剤
JP3770628B2 (ja) * 1994-08-09 2006-04-26 サントリー株式会社 遅延型アレルギー反応を介する医学的症状の予防及び改善剤
WO1996036330A2 (en) 1995-05-17 1996-11-21 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine

Also Published As

Publication number Publication date
EP0790056A1 (de) 1997-08-20
EP0790056B1 (de) 2004-11-10
DK0790056T3 (da) 2005-03-21
CA2201855A1 (en) 1997-02-20
DE69633818D1 (de) 2004-12-16
EP0790056A4 (de) 2002-11-06
KR100458659B1 (ko) 2005-06-27
US20020012690A1 (en) 2002-01-31
PT790056E (pt) 2005-02-28
DE69633818T2 (de) 2005-12-08
ES2232839T3 (es) 2005-06-01
US6765020B2 (en) 2004-07-20
KR100490189B1 (ko) 2005-05-17
JP4111542B2 (ja) 2008-07-02
CA2201855C (en) 2008-11-18
KR20040063978A (ko) 2004-07-15
AU715562B2 (en) 2000-02-03
AU6669096A (en) 1997-03-05
WO1997005863A1 (fr) 1997-02-20
KR970705988A (ko) 1997-11-03

Similar Documents

Publication Publication Date Title
ATE281831T1 (de) Verwendung eines mittels zur zur vorbeugung oder behandlung von durch anomalitäten des knorpelgewebes verursachten erkrankungen
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
PL1780197T3 (pl) 5-podstawione-2-fenyloaminobenzamidy jako inhibitory MEK
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
ATE123943T1 (de) Mittel zur behandlung und vorbeugung von bauchentzündungen, die als wirkstoff zink-l- carnosin-salze oder -komplexe enthalten.
DE59912182D1 (de) Vorrichtung zur behandlung von körpergewebe, insbesondere von oberflächennahem weichgewebe, mittels ultraschall
DE122005000005I2 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz
DE69533176D1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
ATE135208T1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE69832710D1 (de) Nicht-irritierende zusammensetzung zur behandlung des aknes und andere hautzustände
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69916632D1 (de) Verwendung von zimtsäurederivaten zur herstellung eines medikamentes zur vorbeugung oder behandlung von erkrankungen die durch einen hohen blutfettspiegel bedingt sind
EP0699439A3 (de) Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase
DE69614375D1 (de) Dermatologische zubereitung zur behandlung von aktinischen keratosen
AU690853B2 (en) Peptide for inhibiting blood triglyceride level rise and inhibitor for blood triglyceride level rise comprising the peptide as active ingredient
ATE446285T1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ES2153415T3 (es) Peptido inhibidor de la diferenciacion de adipocitos e inhibidor de la diferenciacion de adipocitos que contiene dicho peptido como ingrediente activo.
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
ATE369856T1 (de) Verfahren zur behandlung von glaukom
ATE550039T1 (de) Mittel zur behandlung von glomerulären erkrankungen
DE69317716D1 (de) Verwendung von Fettsäuren zur Behandlung von abnormalen Verkalkung des Gewebes
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0790056

Country of ref document: EP

EEIH Change in the person of patent owner